The Book of Peptides is not a clinic and not your doctor. We do not sell, prescribe, recommend, or personalize any compound, and no grade or ranking here is an endorsement. In the United States, most of these compounds are not FDA-approved and are sold for laboratory research only; a few are prescription drugs, and some are controlled substances or banned in sport. Possessing or administering an unapproved compound outside an authorized setting may be unlawful. Nothing here is a recommendation to buy, possess, or self-administer anything. Consult a licensed physician before any decision involving peptide use.
A GH-axis "base layer" stack that pairs a GHRH analog with a selective ghrelin-receptor agonist to raise endogenous GH/IGF-1 pulses more strongly than either compound alone, aimed at recovery, sleep quality, and body composition rather than acting as a muscle-building compound in its own right.
A three-peptide "full GH/IGF-1 axis" stack meant to hit the same growth-signaling pathway from two directions at once: CJC-1295 + Ipamorelin drive a bigger, more frequent pulse of the body's own growth hormone (and the downstream IGF-1 rise that follows it), while IGF-1 LR3 is injected directly to activate IGF-1 receptors in trained muscle immediately, without waiting on the GH step.
Layers Tesamorelin's on-label, trial-proven visceral-fat-reduction GHRH signal on top of the simpler CJC-1295+Ipamorelin GH-pulse stack, marketed as an escalation product for users who specifically want a fat-targeted GHRH agent added rather than just more of the same non-selective GHRH tone.
A selective ghrelin-receptor agonist, notable for stimulating GH release with comparatively little effect on cortisol, prolactin, or appetite versus older secretagogues. Among the peptides expected back on the legal Category 1 compounding list.
